Response of Relapsed Pancreatoblastoma to a Combination of Vinorelbine and Oral Cyclophosphamide.

Abstract

Pancreatoblastoma is a rare tumor of the pancreas in children, with favorable prognosis if completely resected. If unresectable, neoadjuvant chemotherapy with cisplatin-based regimens are commonly used with good response that allows for resection. For locally aggressive or metastatic disease, neoadjuvant chemotherapy has been reported. Treatment for relapsed or refractory cases is based on anecdotal experiences. We report 2 cases of relapsing pancreatoblastoma with clinical and radiologic response to vinorelbine and cyclophosphamide. Although cure was not achieved, this combination can be offered as an easily tolerated alternative to aggressive chemotherapy for relapsed cases in a palliative setting.

• Authors: Chetan Dhamne, Cynthia E Herzog
• Journal: Journal of pediatric hematology/oncology (J Pediatr Hematol Oncol) Vol. 37 Issue 6 Pg. e378-80 (Aug 2015) ISSN: 1536-3678 [Electronic] United States
• PMID: 26056794 (Publication Type: Case Reports, Journal Article)

Chemical References

• Vinblastine
• Cyclophosphamide
• Vinorelbine

Topics

• Administration, Oral
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Child
• Child, Preschool
• Combined Modality Therapy (adverse effects)
• Cyclophosphamide (administration & dosage)
• Female
• Humans
• Liver Neoplasms (drug therapy, etiology, secondary)
• Lung Neoplasms (drug therapy, etiology, secondary)
• Male
• Neoplasm Recurrence, Local (drug therapy, etiology, pathology)
• Neoplasm Staging
• Pancreatic Neoplasms (complications, pathology, therapy)
• Prognosis
• Vinblastine (administration & dosage, analogs & derivatives)
• Vinorelbine